Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS

Executive Summary

The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month. Novartis also pursuing similar contracts with private payers.

You may also be interested in...



ICER Views CAR-T Therapies Kymriah, Yescarta As Cost Effective

ICER's review of available clinical trial data along with associated treatment and hospital costs found that Novartis' Kymriah and Gilead/Kite's Yescarta generally would not break the health care bank.

CAR-T Commercialization Strategies: Views From Novartis And Kite

At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.

CAR-T Indication-Based Pricing May Be Evaluated In Medicare Demo

Novartis exec discusses details around its agreements with CMS for outcomes based payments and indication-based pricing for Kymriah.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel